Liver Cancer (Feb 2022)

Management of systemic therapies and hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma based on sarcopenia assessment

  • Takahiro Yamasaki,
  • Issei Saeki,
  • Yurika Yamauchi,
  • Toshihiko Matsumoto,
  • Yutaka Suehiro,
  • Tomokazu Kawaoka,
  • Shinsuke Uchikawa,
  • Akira Hiramatsu,
  • Hiroshi Aikata,
  • Kazufumi Kobayashi,
  • Takayuki Kondo,
  • Sadahisa Ogasawara,
  • Tetsuhiro Chiba,
  • Taro Takami,
  • Kazuaki Chayama,
  • Naoya Kato,
  • Isao Sakaida

DOI
https://doi.org/10.1159/000522389

Abstract

Read online

Background: Sarcopenia, defined as the loss of skeletal muscle mass, physical performance, and strength, has been associated with poor clinical outcomes in hepatocellular carcinoma (HCC) patients treated with several therapies. As systemic therapies, including molecular targeted agents, have a strong impact on sarcopenia, we aimed to review the impact of sarcopenia in patients receiving systemic therapies, especially sorafenib and hepatic arterial infusion chemotherapy (HAIC). Summary: Several studies have demonstrated that sarcopenia is associated with poor clinical outcomes in patients receiving sorafenib or lenvatinib, while HAIC has no association with overall survival (OS) and sarcopenia. Furthermore, based on our previous study, we developed the management of sorafenib score (MS score) to stratify patients’ survival according to the positivity of three parameters (skeletal muscle mass, disease control of sorafenib, and post-sorafenib therapy), ranging from 0 to 3. Patients with an MS score ≥2 (median survival time [MST], 16.4 months) showed significantly longer survival than those with an MS score ≤1 (MST, 8.4 months) (p <0.001). This result indicates that patients need at least two positive parameters to prolong OS. Although performance status (PS) has been used in the Barcelona Clinic Liver Cancer staging system, we consider that the assessment of sarcopenia has the potential to replace PS. Key messages: Sarcopenia is associated with poor clinical outcomes in patients of hepatocellular carcinoma receiving sorafenib or lenvatinib. The management of sorafenib (MS) score, based on the positivity of three prognostic factors, including skeletal muscle mass, in patients receiving sorafenib, can be a reliable indicator of prolonged survival.